Portal de Periódicos da CAPES

Serum levels of soluble CD40 ligand and MMP-9 as markers of favorable clinical outcome in human visceral leishmaniasis

2013; Frontiers Media; Volume: 4; Linguagem: Inglês

10.3389/conf.fimmu.2013.02.01064

1664-3224

Oliveira Fabr�cia, Dos Santos Priscila, Silva Carla Vanessa, Damascena Nayra, Passos Rodrigo, Duthie Malcolm, Guderian Jeffrey, De Moura Tatiana, Reed Steven, P Montane de la Roque, De Jesus Am�lia,

Parasites and Host Interactions

Event Abstract Back to Event Serum levels of soluble CD40 ligand and MMP-9 as markers of favorable clinical outcome in human visceral leishmaniasis Fabrícia A. Oliveira1*, Priscila L. Dos Santos1, Carla Vanessa O. Silva1, Nayra P. Damascena1, Rodrigo O. Passos1, Malcolm Duthie2, Jeffrey Guderian2, Tatiana R. De Moura1, Steven G. Reed2, Roque Pacheco1 and Amélia R. De Jesus1* 1 Hospital Universitario /Universidade Federal de Sergipe, Molecular Biology, Brazil 2 Infectious Disease Research Institute, United States Introduction: Soluble CD40 ligand (sCD40L) was described as a marker of cardiovascular diseases. sCD40L and matrix metalloproteinase 9 (MMP-9) are inflammation markers and have been poorly described in infections disease. In this prospective study we describe the sera kinetics of these two molecules in the course of treatment follow up in human visceral leishmaniasis (VL), and compare with the levels of endemic control subjects. Methods and results: Sera from VL patients were collected before and during follow up of regular Antimony treatment. Sera from asymptomatic subjects living either in non endemic regions (unexposed controls) or living in the same households of VL patients living in endemic settings at high risk of infection (endemic controls) were collected as controls. sCD40L and MMP-9 were measured by Luminex assay. While sCD40L and MMP-9 were not detected in sera from unexposed controls, elevated levels were observed in sera from VL patients, with a gradual increase in both sCD40L and MMP-9 levels during the follow-up of VL patients undergoing antimony treatment. sCD40L levels were also high in endemic controls. Additionally, negative correlations were found between spleen sizes and MMP-9 before treatment and sCD40L at day 15 of treatment. Conclusion: Our findings suggest that elevated sCD40L and MMP-9 levels are associated with resistance to infection and clinical resolution of VL. Acknowledgements Financial support: Fundação de Apoio à Pesquisa e à Inovação Tecnológica do Estado de Sergipe (FAPITEC)/ Brazilian Research National Council (CNPq)/Ministério da Saúde (Programa de Apoio a Projetos para o Sistema Único de Saúde – PPSUS Edital 08/2009 and Programas de Núcleos de Excelência – PRONEX), Bill & Melinda Gates Foundation, USA. Programa Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES). Keywords: sCD40L, MMP-9, sera kinetics, human, Visceral leishmaniasis Conference: 15th International Congress of Immunology (ICI), Milan, Italy, 22 Aug - 27 Aug, 2013. Presentation Type: Abstract Topic: Adaptive Immunity Citation: Oliveira FA, Dos Santos PL, Silva CO, Damascena NP, Passos RO, Duthie M, Guderian J, De Moura TR, Reed SG, Pacheco R and De Jesus AR (2013). Serum levels of soluble CD40 ligand and MMP-9 as markers of favorable clinical outcome in human visceral leishmaniasis. Front. Immunol. Conference Abstract: 15th International Congress of Immunology (ICI). doi: 10.3389/conf.fimmu.2013.02.01064 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 30 Jun 2013; Published Online: 22 Aug 2013. * Correspondence: Miss. Fabrícia A Oliveira, Hospital Universitario /Universidade Federal de Sergipe, Molecular Biology, Aracaju, Sergipe, 49045250, Brazil, fa_alvisi@hotmail.com Dr. Amélia R De Jesus, Hospital Universitario /Universidade Federal de Sergipe, Molecular Biology, Aracaju, Sergipe, 49045250, Brazil, jesus-amelia@uol.com.br Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Fabrícia A Oliveira Priscila L Dos Santos Carla Vanessa O Silva Nayra P Damascena Rodrigo O Passos Malcolm Duthie Jeffrey Guderian Tatiana R De Moura Steven G Reed Roque Pacheco Amélia R De Jesus Google Fabrícia A Oliveira Priscila L Dos Santos Carla Vanessa O Silva Nayra P Damascena Rodrigo O Passos Malcolm Duthie Jeffrey Guderian Tatiana R De Moura Steven G Reed Roque Pacheco Amélia R De Jesus Google Scholar Fabrícia A Oliveira Priscila L Dos Santos Carla Vanessa O Silva Nayra P Damascena Rodrigo O Passos Malcolm Duthie Jeffrey Guderian Tatiana R De Moura Steven G Reed Roque Pacheco Amélia R De Jesus PubMed Fabrícia A Oliveira Priscila L Dos Santos Carla Vanessa O Silva Nayra P Damascena Rodrigo O Passos Malcolm Duthie Jeffrey Guderian Tatiana R De Moura Steven G Reed Roque Pacheco Amélia R De Jesus Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.